Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.45 |
| ▸ | RHOC | P08134 | 1/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326894 | 1.00 | TP53 (0.52) | TP53MAPTHRH3CCR2KCNH2 | |
| SCHEMBL3330095 | 0.88 | DRD2 (0.48) | MAPTSMN1; SMN2 | |
| SCHEMBL3330093 | 0.88 | DRD2 (0.48) | MAPTSMN1; SMN2 | |
| SCHEMBL3321818 | 0.87 | CCR2 (0.51) | MAPTHRH3CCR2KCNH2TSHR | |
| SCHEMBL3321822 | 0.87 | CCR2 (0.51) | MAPTHRH3CCR2KCNH2TSHR | |
| SCHEMBL3328036 | 0.80 | POLB (0.49) | MAPTHRH3CNR1KMT2APOLB | |
| SCHEMBL3325780 | 0.80 | LMNA (0.52) | HRH3KCNH2CNR1KMT2APOLB | |
| SCHEMBL3326452 | 0.80 | LMNA (0.52) | HRH3KCNH2CNR1KMT2APOLB | |
| SCHEMBL3325775 | 0.80 | LMNA (0.52) | HRH3KCNH2CNR1KMT2APOLB | |
| SCHEMBL3323894 | 0.80 | POLB (0.49) | MAPTHRH3CNR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | TP53 4145/4885MAPT 3053/4885HRH3 1/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | TP53 4145/4885MAPT 3053/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.